SRR8526731
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.470
- OXIDATIVE_PHOSPHORYLATION+0.440
- MTORC1_SIGNALING+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- E2F_TARGETS+0.330
- GLYCOLYSIS+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.270
- G2M_CHECKPOINT+0.240
- ADIPOGENESIS+0.210
Top 10 suppressed
- UV_RESPONSE_DN-0.370
- ANGIOGENESIS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- HEDGEHOG_SIGNALING-0.240
- TGF_BETA_SIGNALING-0.210
- ANDROGEN_RESPONSE-0.160
- MITOTIC_SPINDLE-0.160
- KRAS_SIGNALING_UP-0.150
- COAGULATION-0.140
- APICAL_JUNCTION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016960 | — | — | 0.840 |
| 2 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.821 |
| 3 | SRR6013558 | — | cohortA4 | 0.814 |
| 4 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.809 |
| 5 | C3N-01419 | — | cohortA1 | 0.805 |
| 6 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.803 |
| 7 | SRR11296765 | — | — | 0.798 |
| 8 | ERR2278852 | — | — | 0.788 |
| 9 | TCGA-33-4583-01A-01R-1443-07 | — | cohortSQ2 | 0.785 |
| 10 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |